Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Stegeman, Hanneke ^a   Kaanders, Johannes H ^a   Wheeler, Deric L ^b   van der Kogel, Albert J ^a   Verheijen, Marieke M ^a   Waaijer, Stijn J ^a   Iida, Mari ^b   Grénman, Reidar ^c   Span, Paul N ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

EGFR; Head and neck cancer; Hypoxia; pAKT; Tumor microenvironment

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXYGEN; PROTEIN KINASE B; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER TISSUE; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANOXIA; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK NEOPLASMS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NITROIMIDAZOLES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867206311     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-463     Document Type: Article

References (29)

1. Davies L, Welch HG. Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 2006, 135(3):451-457. 10.1016/j.otohns.2006.01.029, 16949981.
2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578. 10.1056/NEJMoa053422, 16467544.
3. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010, 7(9):493-507. 10.1038/nrclinonc.2010.97, 2929287, 20551942.
4. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006, 12(13):4103-4111. 10.1158/1078-0432.CCR-05-2404, 16818711.
5. Yamatodani T, Ekblad L, Kjellen E, Johnsson A, Mineta H, Wennerberg J. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 2009, 135(3):395-402. 10.1007/s00432-008-0475-2, 18813952.
6. Bonner JA, Yang ES, Trummell HQ, Nowsheen S, Willey CD, Raisch KP. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol 2011, 99(3):339-343. 10.1016/j.radonc.2011.05.070, 21704410.
7. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000, 19(21):2489-2495. 10.1038/sj.onc.1203483, 10851047.
8. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9(3):288-296. 10.1016/S1470-2045(08)70073-1, 18308254.
9. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der Kogel AJ, et al. Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial. J Clin Oncol 2012, 30(15):1777-1783. 10.1200/JCO.2011.35.9315, 22508814.
10. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25(26):4066-4074. 10.1200/JCO.2007.12.7878, 17827455.
11. Rademakers SE, Span PN, Kaanders JH, Sweep CGJ, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008, 2:41-53. 10.1016/j.molonc.2008.03.006, 19383328.
12. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal 2009, 21(8):1255-1268. 10.1016/j.cellsig.2009.02.021, 2770888, 19258037.
13. Giro C, Berger B, Bolke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009, 90(2):166-171. 10.1016/j.radonc.2008.09.007, 18977050.
14. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47. 10.1038/nrc704, 11902584.
15. Thariat J, Etienne-Grimaldi MC, Grall D, Bensadoun RJ, Cayre A, Penault-Llorca F, Veracini L, Francoual M, Formento JL, Dassonville O, et al. Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Clin Cancer Res 2012, 18(5):1313-1322. 10.1158/1078-0432.CCR-11-2339, 22228639.
16. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A 2007, 104(32):13092-13097. 10.1073/pnas.0702387104, 1941796, 17670948.
17. Wang X, Schneider A. HIF-2{alpha}-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 2010, 31(7):1202-1210. 10.1093/carcin/bgq078, 2893799, 20395290.
18. Kim TR, Cho EW, Paik SG, Kim IG. Hypoxia-induced SM22alpha in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy. FEBS Lett 2012, 586(4):303-309. 10.1016/j.febslet.2011.12.036, 22245152.
19. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J, Curti C. SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification. Oral Oncol In press.
20. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008, 15(4):1193-1201. 10.1245/s10434-007-9771-3, 18172732.
21. Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD, Chen MF. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010, 76(4):1214-1224. 10.1016/j.ijrobp.2009.09.059, 20206020.
22. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008, 105(2):692-697. 10.1073/pnas.0707270105, 2206598, 18180459.
23. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27(28):3944-3956. 10.1038/onc.2008.19, 2903615, 18297114.
24. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501. 10.1038/nrc839, 12094235.
25. Knowles JA, Golden B, Yan L, Carroll WR, Helman EE, Rosenthal EL. Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Laryngoscope 2011, 121(11):2359-2365. 10.1002/lary.22180, 3396129, 22020886.
26. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 2010, 5(11):e14124. 10.1371/journal.pone.0014124, 2993951, 21124782.
27. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, et al. Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. Clin Cancer Res In press.
28. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8(3):180-192. 10.1038/nrc2344, 18273037.
29. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005, 20(7):575-579. 10.1007/s10654-005-7835-x, 16119429.